DVT treatment in 2000: State of the art

Orthopedics

Volumn 23, Issue 6 SUPPL., 2000, Pages

  Davidson, Bruce L ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN;

BLOOD CLOT LYSIS; CONFERENCE PAPER; COST CONTROL; DEEP VEIN THROMBOSIS; DRUG SAFETY; HEALTH CARE DELIVERY; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOGRAPHY; RELIABILITY; SUPERIOR CAVA VEIN; ULTRASOUND THERAPY;

ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LEG; RISK FACTORS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; VENA CAVA FILTERS; VENOUS THROMBOSIS;

EID: 0033946092     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Murray DWG, Jacques LB, Peirett TS, Best CH. Heparin and the thrombosis of veins following injury. Surgery. 1937; 2:163-187.
2. Stahman MA, Hòbner CF, Link KP. Studies on the hemorrhagic Sweet clover disease V. Identification of the hemorrhagic agent. J Biol Chem. 1941; 138:513-527.
3. Siragusa S, Cosmi B, Piovella F et al. Low-molecular-weight heparin and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a metaanalysis. Am J. Med. 1996; 100:269-277.
4. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis. Br Med J. 1994; 309:299-309.
5. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins in the initial treatment of deep venous thrombosis: An updated meta-analysis. Drugs. 1996; 52(suppl 7):30-37.
6. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med. 1995; 155:601-607.
7. Hull RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992; 326:975-982.
8. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996; 334:677-681.
9. Koopman MMW, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996; 334:682-687.
10. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997; 337:657-662.
11. Partsch H, Kechavarz B, Mostbeck A et al. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin. J Vasc Surg. 1996; 24:774-782.
12. Lindmarker P, Homstrøm M, Granqvist S et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1994; 72(2):186-190.
13. Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost. 1996; 76(2):195-199.
14. Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once and twice-daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis [abstract]. American Society of Hematology, San Diego, December 1997:1305.
15. Lohr JM, James KV, Deshmukh RM, Kasselfeld KA. Allastair B Karmody award. Calf vein thrombi are not a benign finding. Am J Surg. 1995; 170(2):86-90.
16. Decousus H, Leizorovicz A, Parent F et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998; 338:409-415.
17. Grossman C, McPherson S. Safety and efficacy of catheter-directed thrombolysis for iliofemoral venous thrombosis. Am J Roentgenol. 1999; 172:667-672.
18. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet. 1992; 340:873-876.
19. Schulman S, Rhedin A-S, Lindmarker P et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995; 332:1661-1665.
20. Schulman S, Granqvist S, Holmstrøm M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997; 336:393-398.